Literature DB >> 6146707

Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines.

P Bousquet, J Feldman, J Schwartz.   

Abstract

To check whether the central hypotensive effect of alpha adrenergic agonists is linked with the stimulation of alpha-2 receptors, such drugs were administered directly to the nucleus reticularis lateralis, which is an important site for the hypotensive action of clonidine. These experiments were carried out by microinjections (0.5 microliter on each side) in normotensive cats anesthetized with pentobarbital. alpha-Methylnorepinephrine, a selective alpha-2 agonist (0.1-10 micrograms/kg) had no hypotensive effect in this region, whereas potent alpha-1 agonists such as cirazoline (0.01-1 micrograms/kg) and ST 587 (1-10 micrograms/kg), like clonidine, produced dose-dependent hypotensive effects. Our results suggest that alpha-2 selective catecholamines are not active in the nucleus reticularis lateralis region, whereas imidazolines induce a hypotensive effect whatever their affinity for one subtype of alpha adrenoceptors. Therefore, there may be some form of structure-activity relationship which would indicate the existence, in this particular region of the medulla oblongata, of sites preferring the imidazoline structure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146707

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  71 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs.

Authors:  V Bruban; J Feldman; H Greney; M Dontenwill; S Schann; C Jarry; M Payard; J Boutin; E Scalbert; B Pfeiffer; P Renard; P Vanhoutte; P Bousquet
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 3.  Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?

Authors:  Andrew Holt
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

Review 4.  Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.

Authors:  P Bousquet; J Feldman
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

5.  Change in the Binding of [11C]BU99008 to Imidazoline I2 Receptor Using Brain PET in Zucker Rats.

Authors:  Kazunori Kawamura; Tomoteru Yamasaki; Yiding Zhang; Hidekatsu Wakizaka; Akiko Hatori; Lin Xie; Masayuki Fujinaga; Ming-Rong Zhang
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

6.  Central alpha-2 adrenoceptors are responsible for a clonidine-induced cue in a rat drug discrimination paradigm.

Authors:  S Jordan; H C Jackson; D J Nutt; S L Handley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Differential blocking actions of idazoxan against the inhibitory effects of 6-fluoronoradrenaline and clonidine in the rat vas deferens.

Authors:  P E Hicks; S Z Langer; A D Macrae
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

8.  Alpha 2-adrenergic hyperpolarization is not involved in slow synaptic inhibition in amphibian sympathetic ganglia.

Authors:  P E Rafuse; P A Smith
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

9.  The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin.

Authors:  J A Ruiz-Ortega; L Ugedo; J Pineda; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

10.  The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain.

Authors:  G Olmos; R Alemany; P V Escriba; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.